Search everything Menu Media Our latest news, announcements and multimedia resources Latest news News releasesCompany statements November 30, 2021 Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults November 30, 2021 Merck Announces First-Quarter 2022 Dividend November 30, 2021 Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma November 30, 2021 FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review November 29, 2021 European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma November 29, 2021 European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma View all Media resources News releases Read our latest news releases. Company statements Read our latest company statements. Media library Access videos, logos, photos and infographics. Media contact details General General media inquiries +1 908-740-5633 mediarelations@merck.com Patrick Ryan Corporate media relations +1 973-275-7075 patrick.ryan4@merck.com John Cummins Policy media relations +1 202-508-4567 john.cummins2@merck.com Get to know us through our stories Everything we do, in and out of the laboratory, is based on our deep appreciation for life. Get a glimpse of what it's like on the inside through our stories. Read on We are driven by a shared purpose to invent for life Our mission is to discover, develop and provide innovative products and services that save and improve lives around the world. Learn more about our company Investor relations Find our latest financials, events & presentations, news, stock information and investor contacts. Visit investor relations Company fact sheet Access company information including stock ticker, official company names, description, and more. See company fact sheet Sign up for email alerts Receive company news, updates and other information Unsubscribe from email alerts Connect with us on social For patients and health care professionals MerckHelps Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients Merck Access Program Information about insurance coverage and financial assistance options for eligible patients Clinical trials Learn about our clinical trials and find available studies Merck Manuals Medical information source covering thousands of topics in all fields of medicine Corporate responsibility Environmental, Social, Governance (ESG) Report Reporting on our commitment to operating responsibly to benefit society Merck for Mothers An initiative to create a world where no woman has to die giving life About Merck Merck Animal Health The global animal health business unit of Merck Forward-looking statement Cookie policy Cookie Preferences Privacy Transparency disclosure Terms of use Sitemap Copyright © 2009-2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. This Site Uses Cookies and Your Privacy Choice Is Important to Us We suggest you choose Customize My Settings to make your individualized choices. Accept All Cookies means that you are choosing to accept third-party Cookies and that you understand this choice. See our Privacy Policy Customize My Settings Accept All Cookies